Naomi B. Zak
Dr. Zak holds a Ph.D. from Harvard Medical School and completed a postdoctoral fellowship at the Weizmann Institute of Science. Dr. Zak has over 15 years of leadership experience in the biotech industry in a range of executive capacities, including: manager of regulatory affairs at Chiasma, a clinical stage company developing oral formulations for medications currently administered parenterally; and director of R&D in both IDgene, a gene discovery company, and CellCure, a clinical stage company developing human embryonic stem cell based therapies. More recently, she served as interim CEO of ProtAb and as CEO of SCTherapeutics. Dr. Zak has led company launching activities, target indication assessment, establishment of research platforms, and product development activities.